4D Molecular Therapeutics, Inc. (FDMT)
$
3.71
+0.24 (6.47%)
Key metrics
Financial statements
Free cash flow per share
-2.7535
Market cap
161.7 Million
Price to sales ratio
18 Thousand
Debt to equity
0.0508
Current ratio
12.3635
Income quality
0.8686
Average inventory
0
ROE
-0.3327
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that specializes in developing product candidates based on adeno-associated virus vectors. The company focuses on three key therapeutic areas: ophthalmology, cardiology, and pulmonology, thereby addressing significant medical needs. Currently, it has three product candidates in clinical trials, including 4D-125, which is undergoing a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, 4D-110 in a Phase 1/2 trial for choroideremia, and 4D-310, also in a Phase 1/2 trial for Fabry disease. Additionally, the company has two Investigational New Drug (IND) candidates: 4D-150 aimed at treating wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The gross profit stands at $37,000.00 highlighting the company's profitability from core operations. The operating income ratio is -5,076.78 indicating the company's operational profitability margin. The operating expenses amount to $187,878,000.00 encompassing various operational costs incurred. The company achieved a revenue of $37,000.00 indicating its niche market focus, while the weighted average number of shares outstanding is 53,943,741.00 highlighting the company's shareholder base. In the financial landscape, the stock is affordable at $3.71 suitable for budget-conscious investors. It has an average trading volume of 644,137.00 indicating moderate liquidity that facilitates trading activity. With a market capitalization of $171,864,266.00 the company is classified as a small-cap player, which often allows for more significant growth potential compared to larger firms. Furthermore, 4D Molecular Therapeutics is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, which drives innovation and growth, positioning the company as a promising entity within its field.
Is 4D Molecular Therapeutics, Inc. (FDMT) a good investment?
Investing in 4D Molecular Therapeutics, Inc. (FDMT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is 4D Molecular Therapeutics, Inc. (FDMT)'s stock forecast?
Analysts predict 4D Molecular Therapeutics, Inc. stock to fluctuate between $2.24 (low) and $28.93 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is 4D Molecular Therapeutics, Inc.'s market capitalization?
As of 2025-05-30, 4D Molecular Therapeutics, Inc.'s market cap is $171,864,266, based on 46,324,600 outstanding shares.
How does 4D Molecular Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, 4D Molecular Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy 4D Molecular Therapeutics, Inc. (FDMT) stock?
To buy 4D Molecular Therapeutics, Inc. (FDMT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FDMT. Place an order (Market, Limit, etc.).
What is the best time to invest in 4D Molecular Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did 4D Molecular Therapeutics, Inc. perform in the last earnings report?
Revenue: $37,000 | EPS: -$2.98 | Growth: 15.50%.
Where can I find 4D Molecular Therapeutics, Inc.'s investor relations reports?
Visit https://www.4dmoleculartherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for 4D Molecular Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for 4D Molecular Therapeutics, Inc. stock?
All-time high: $55.11 (2021-02-11) | All-time low: $2.24 (2025-04-09).
What are the key trends affecting 4D Molecular Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
3 days ago
EMERYVILLE, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings.
globenewswire.com
14 days ago
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
zacks.com
22 days ago
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago.
globenewswire.com
22 days ago
EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined expected upcoming milestones.
globenewswire.com
a month ago
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings.
globenewswire.com
a month ago
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME).
globenewswire.com
2 months ago
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company's board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
globenewswire.com
2 months ago
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings.
globenewswire.com
3 months ago
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (wet AMD).
globenewswire.com
3 months ago
EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2024 financial results, provided operational highlights and outlined expected upcoming milestones.
See all news
